Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch & Lomb Inc.

Division of Valeant Pharmaceuticals International Inc.

Latest From Bausch & Lomb Inc.

Valeant Claims Progress, Asks Investors For Patience

The Canadian specialty pharma has exceeded its near-term debt-reduction goals, but are its plans for a return to growth grounded in reality? Market analysts recommend caution, but see some reason for optimism.
Sales & Earnings Business Strategies

India's Device Price Cap Storm Rages On: New Stent Cap And Spotlight On Catheter Trade Margins

India’s medical device pricing storm looks unlikely to abate any time soon, with another round of price caps on stents being enforced. The spotlight is also shining on the sharp variances in trade margins for catheters in the country.
India Pricing Debate

Melinta: A Pure-Play Antibiotics Specialist Rises

CEO Daniel Wechsler talked with Scrip about being a pure-play specialist in the challenging antibiotics market, following the acquisition of The Medicines Co.'s anti-infectives franchise and a reverse merger with Cempra last year.

Business Strategies Infectious Diseases

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.

Ophthalmic Market Intelligence
See All

Company Information